If your doctor recently prescribed Repatha to help lower your "bad" LDL cholesterol and reduce the risk of heart disease, you may be wondering how it fits into the bigger picture of heart health.

Amgen (NASDAQ: AMGN) today announced new findings showing Repatha® (evolocumab) reduced the risk of death in high-risk adults without a prior heart attack or stroke when added to statins or other ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Amgen (AMGN) said new findings from a pre-specified Phase 3 VESALIUS-CV trial analysis showed Repatha (evolocumab) reduced the risk of death by 20% in high-risk adults without a prior heart attack or ...

Amgen said Monday its cholesterol buster, Repatha, reduced the risk of death by 20% in a study of more than 12,000 high-risk ...

--Amgen today announced new Repatha ® combined data from the Phase 3 FOURIER and FOURIER Open Label Extension studies and the Phase 2 OCEAN- DOSE study of investigational olpasiran, an siRNA that ...

--Amgen today announced the presentation of 12 cardiovascular scientific research abstracts, including clinical trial and real-world evidence studies of Repatha ®, that add to the growing body of ...

Phase 3 VESALIUS-CV trial showing that Repatha (evolocumab) reduced the risk of death by 20% in adults at high risk for a first heart attack ...